Evidence map›Paper›PMID 34014767›Full record

ArticleCancer biotherapy & radiopharmaceuticals2021

Jyoti Roy, Elaine M Jagoda, Falguni Basuli, Olga Vasalatiy, Tim E Phelps, Karen Wong, Anita T Ton, Urs B Hagemann, Alan S Cuthbertson, Patricia E Cole and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biotherapy & radiopharmaceuticals, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Evaluation of Candidate Theranostics forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
    Article
  7. Toward OptimizedPharmaceutics · 2022
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Jyoti RoyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Elaine M JagodaMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Falguni BasuliChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, Maryland, USA.
Olga VasalatiyChemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, Maryland, USA.
Tim E PhelpsMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Karen WongMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Anita T TonMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Urs B HagemannBayer AG, Pharmaceutical Division, Berlin, Germany.
Alan S CuthbertsonBayer AS, Thorium Conjugate Research, Oslo, Norway.
Patricia E ColeBayer USA, LLC, Whippany, New Jersey, USA.
Raffit HassanThoracic and GI Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Frank I LinMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
National Institutes of Health · USNational Heart Lung and Blood Institute · USBayer (Germany) · DEBayer (Norway) · NOBayer (United States) · US

Funding

Intracellular In vivo ImagingZIABC010657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$20.3M
Instrumentation for microSPECT and microPET imagingZIABC010668 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$11.0M
Th227-mesothelin antibody conjugate in mesotheliomaZIABC011825 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LIN, FRANK · 2018 to 2022
$383k
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsChelating AgentsDeferoxamineFemaleHumansImmunoconjugatesMaytansineMesothelinMiceMice, NudeRadioisotopesZirconiumanetumab ravtansineChelating AgentsDeferoxamineImmunoconjugatesMaytansineMesothelinMSLN protein, humanMsln protein, mouseRadioisotopesZirconiumZirconium-8932-HOPOantibody conjugateDFOmesothelinPET imagingzirconium-89

Identifiers

PMID34014767
PMCPMC8161658
OpenAlexW3160048097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.